Pavel Raifeld
Chief Executive Officer at INNOVIVA, INC.
Net worth: 184 206 $ as of 30/05/2024
Profile
Pavel Raifeld is currently the Chief Executive Officer at Innoviva, Inc. He is also the Chief Executive Officer at Theravance Respiratory Co. LLC.
Additionally, he holds the position of Director at La Jolla Pharmaceutical Co. and Entasis Therapeutics Holdings, Inc. Mr. Raifeld previously worked as a Senior Member-Healthcare Investment Banking at Credit Suisse Securities (USA) LLC.
He holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from Harvard University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
INNOVIVA, INC.
0.02% | 17/04/2024 | 11,666 ( 0.02% ) | 184 206 $ | 30/05/2024 |
Pavel Raifeld active positions
Companies | Position | Start |
---|---|---|
INNOVIVA, INC. | Chief Executive Officer | 19/05/2020 |
ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Board Member | 10/07/2022 |
LA JOLLA PHARMACEUTICAL COMPANY | Director/Board Member | 21/08/2022 |
Theravance Respiratory Co. LLC
Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Chief Executive Officer | - |
Former positions of Pavel Raifeld
Companies | Position | End |
---|---|---|
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Pavel Raifeld
The Trustees of Columbia University in The City of New York | Masters Business Admin |
Harvard University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
INNOVIVA, INC. | Health Technology |
Private companies | 4 |
---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Finance |
Theravance Respiratory Co. LLC
Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Pavel Raifeld